Skip navigation
Watchlist Sponsored By :


Current DateTime: 06:00:29 10 Feb 2012
LinksList Documentid: 24355697
  • The World's Best Beers

      Craft brewers account for only about five percent of the US market, but that may be changing.

  • Fashion Stocks Traders Love

      Over the past couple of months, the “Fast Money” traders weighed in on companies that stood out.

  • Best in Show

      Who is the top dog at the Westminster Kennel Club Dog Show


Current DateTime: 06:00:30 10 Feb 2012
LinksList Documentid: 23452764
Expiration DateTime: 2/10/2012 6:03:24 PM

MOST SHARED


Current DateTime: 06:00:31 10 Feb 2012
LinksList Documentid: 31330905
Expiration DateTime: 2/10/2012 6:03:45 PM

MOST POPULAR


Current DateTime: 06:00:32 10 Feb 2012
LinksList Documentid: 35819650
    • Road Warriors

        All the gadgets and gear a savvy frequent traveler needs to navigate the global economy.

HOT ON FACEBOOK

Lowering Cholesterol May Boost Cancer Risk, Study Says

Published: Monday, 23 Jul 2007 | 5:03 PM ET
Text Size
By: Mike Huckman

A new study shows lowering cholesterol could increase the risk of cancer.

The Journal of the American College of Cardiology reports that researchers observed as much as triple the incidence of cancer among patients who lowered their bad or LDL cholesterol using the popular drugs known as statins. The rate, the study says, was especially high among patients with cholesterol levels below 160.

But they don't know if the cancer was caused by the drug, the low cholesterol or happenstance. The doctors who did the study say the heart benefits of statins still outweigh the risk of cancer and that patients should not stop taking their medication.

Researchers looked at the results of clinical trials involving more than 75,000 people who took statins. They're the

biggest segment of the drug industry accounting for $18 billion in sales in 2006, according to Verispan, which monitors prescriptions.

Pfizer's [PFE  Loading...      ()   ] Lipitor, Merck [MRK  Loading...      ()   ] and Schering-Plough's [SGP  Loading...      ()   ] Vytorin and AstraZeneca's [AZN  Loading...      ()   ] Crestor are among the top-selling brand-name statins.

The editor of JACC says the staff debated for three weeks whether to publish this study, but in the end decided that "these findings could not be ignored, that they did warrant further investigation, and that they should be aired in public."

Pfizer, which makes the world's top-selling statin, Lipitor, called the JACC study limited. The company said similar, larger analyses have shown no increased risk of cancer on the drug and that a company-sponsored clinical trial of 10,000 patients also showed no increased risk of cancer death.

Pfizer also said that the JACC study indicates no causal relationship between statins and cancer.

© 2012 CNBC.com

CNBC HIGHLIGHTS

  • Alternative Investing: A CNBC Special Report
  • Marketing clichés aside, sometimes diamonds are for investing.
  • Nordstrom
  • The ‘Fast Money’ traders weigh in on fashion related stocks from apparel to footwear.
  • Las Vegas
  • This list of the 10 most active cities for speed traps was compiled by Trapster.com. See if your town is there.
  • This Valentine’s Day should prove a love fest for restaurants, as many couples will be dining out.
  • Airdale Terrier
  • Here’s a look at Westminster Kennel Club’s most successful breeds—and how much they cost.
  • Jennifer Aniston and Justin Theroux home
  • What kind of homes do celebrity couples share? Here’s our updated list. Take a look.


Current DateTime: 09:37:11 10 Feb 2012
LinksList Documentid: 29778428

Current DateTime: 02:33:42 10 Feb 2012
LinksList Documentid: 29779196

Current DateTime: 11:35:14 10 Feb 2012
LinksList Documentid: 29779197

Current DateTime: 02:56:31 10 Feb 2012
LinksList Documentid: 29779199
CNBCCNBC
About CNBC  |  Site Map  |  Video Reprints   |  Advertise  |  Help  |  Contact
Privacy Policy  |     |  Terms of Service  |  Independent Programming Report
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2012 CNBC LLC.  All Rights Reserved.
A Division of NBCUniversal
Thomson ReutersThomson Reuters